Tap into these articles provided by industry leaders and resources

FUNDING

• Robert Dellenbach, Genetic Engineering & Biotechnology News, outlines dramatic changes in the environment for investing in the life science industry. VC Funding for Biotech Companies Withering: Money Is Still There, but Traditional Biotechs Face More Competition from Emerging Clean Energy Firms
• J. Leslie Glick, Ph.D., Genetic Engineering & Biotechnology News, reviews how VC funding for biotech has fared over the years relative to total funds available, and highlights prospects for the future. VC Funding for Biotech Firms Past Performance and Future Prospects
• Amanda Lyle, BioWorld Perspectives, explores ways to find money in a challenging VC market. VC Investment in 2009: Challenges, Hope and a Guide for Finding Money
• Barbara Schilberg, Genetic Engineering & Biotechnology News, emphasizes that knowing the strategic direction of your company and how it fits in the competitive landscape is vital. Tips for Emerging Firms on Obtaining Funding: Strong IP Portfolio and Therapeutic Focus as well as Understanding Potential Backers Are Vital
• Steve Hurwitz, Choate Hall & Stewart, discusses the importance of your executive summary in raising funds. Seeking US Venture Capital: The Importance of Your Executive Summary

PARTNERING

• David Newble and Professor David J. Williams, discuss partnering and its effects in developing application relevance. Partnering Insights
• Craig Eslinger, PPD, Inc, explains uncertainties that pharmaceutical and biotech companies will experience during rough times for quite some time in the future, requiring us to work smarter and more efficiently if we’re to survive. Partnering for Volatile Times
• Genetic Engineering & Biotechnology News, holds a roundtable discussion and finds out why biopharmaceutical industry deals are growing at an ever-increasing rate. What's Driving Dealmaking in Biopharma? Licensing and Business Development Experts Share Their Insights on M&A and Partnering
• Amanda Lyle, BioWorld Perspectives, talks to the experts and gets their tips for successful partnering. Keys to Success: Experts Offer Tips for All Stages of Partnering
• Amanda Lyle, BioWorld Perspectives, asks Big Pharma companies what they look for in a licensing candidate and other questions about partnering. Partnering Execs Give Perspective on Current and Future Trends
• Stewart Lyman, Ph.D., Genetic Engineering & Biotechnology News, encourages companies to explore scientific arenas beyond their core areas of expertise through valuable research collaborations. Partnerships Expedite Product Advancement: Research Collaborations Often Assist with Candidate Selection and Enhance Future Revenue
• Samuel Murphy, Dan Ross, Simon-Kucher & Partners, discuss three sources for new compounds that drugmakers useto strengthen pipelines. Looming Patent Expirations Inspire Increased Licensing Activity

BUSINESS OPERATIONS

• James C. Greenwood, Genetic Engineering & Biotechnology News, highlights how biotechnology innovations are healing, fueling and feeding the world. BioInsights: Biotech Industry Success Powered by Innovation - Patent Reform and Biosimilars Policies Must Not Hamper the Industry's Contribution
• Michael K. Launer, PhD, RussTech Language Services, Inc., explains how retaining the services of an experienced US translation company can save you money. Managing Risk and Controlling Costs When Conducting Clinical Trials Overseas: Why You Need a Language Services Company on Your Team
• Ana T. Menendez, Catalent Pharma Solutions, highlights important questions and steps to set timelines and prepare for a successful bioassay transfer. A Guide to Accelerating Bioassay Transfer in the GMP Environment
• David Sable, M.D., Genetic Engineering & Biotechnology News, argues that while there is value to be found in biotech, biotech is not true value investing. The Paradox of Biotechnology Value Investing: Assessing Worth Could Be More than Just Conjecture if the Right Tools Are Used
• Dawn E. Ely, Palladium Cheif Legal Officers,writes about acquiring the resources to continue development.Re-think Your Business Model for Success inthe Current Economy

THE ECONOMY & BIOTECH

• Daniel Ruppar, Genetic Engineering & Biotechnology News, says big companies buying up smaller ones won’t keep promising drug therapies from coming to market and saving lives. Preparing for a Shrinking Economic World, Big Pharma Is Well Positioned to Ride Out the Turmoil and Take Biotech Along with It
• Peter Winter, Genetic Engineering & Biotechnology News, sees a market return in early 2010 supported by overseas partnerships and financing deals. Biotech's Umbilical Cord Has Been Severed: Capital Will be More Expensive and Difficult to Obtain in the Next Twelve to Eighteen Months
• Ralph Villiger and Boris Bogdan, Partners at Avance, survey the impact the economic downturn has had on the drug development industry. Survey on the Financial Crisis and the Impact on Biotech and Pharma
• Eric S. Langer, BioPlan Associates, Inc., writes about the path of biopharma and today'sindustry challenges. Biopharma Faces the Future: Results of the 2009 BioPlan Survey

GLOBAL BIOTECH NEWS

• Lawrence Bivins, Life Science Clusters, details how the new Global Innovation Network (GIN) is giving promising start-up firms inside member regions the chance to think, operate and succeed globally. Global Innovation Network: International Consortium Seeks to Speed Emergence of New Clusters
• Bronwyn J. Dilley, Chief Executive NZBIO, believes a strong partnership between Government, industry and the education system will transform and New Zealand’s bioeconomy. The Bioeconomy: A Path to Economic Sustainability
• Gail Dutton, Genetic Engineering & Biotechnology News, offers up tips for doing business in China and India. GEN Review BIO 2008: Tips for Doing Business in China and India - Risks, IP, Opportunities, and Approaches Are Morphing at Breakneck Speed
• Michael Harris, Kathleen Kite-Powell and Amanda Lyle, BioWorld Today, describes how Brazil is a "how-to" model for production and integration of carbon dioxide omission-cutting biofuels. As the Saudi Arabia of Ethanol, Brazil Leads by Example
• Chad Nickel, Integrated Project Management Company, Inc., discusses project management as a strategic weapon. Bringing Order to Global Crisis

U.S. REGIONAL BIOTECH NEWS

• Lawrence Bivins, Life Science Clusters, describes a multi-county initiative aimed at growing North Carolina's already impressive biotech presence, North Carolina's BioEast Alliance Links Life Science Firms to the Future
• Patrick Kelly and Emily Ascherl, BIO State Government Relations; and Pete Pellerito, PMP Consulting, identify key examples of some state efforts to grow and sustain bioscience industry development. State Legislative Best Practices in Support of Bioscience Industry Development

LEGAL & REGULATORY ISSUES

• Courtenay C. Brinckerhoff, Genetic Engineering & Biotechnology News, reports the Quanta decision may impact biotech licenses in several respects. Enforceability of Patent Licenses Under Fire: Supreme Court Ruling in Quanta Has Implications for Biotechnology Industry
• Courtenay C. Brinckerhoff, Genetic Engineering & Biotechnology News, questions whether meaningful patent reform aimed at lowering costs for biotech companies is on the horizon. Court Blocks PTO-Initiated Patent Reform: If Congress Gets Involved, the Outcome Won’t Necessarily Be Any Better for Biotech Firms
• Courtenay C. Brinckerhoff, Genetic Engineering & Biotechnology News, makes innovators seeking to protect their inventions in several countries aware of the similarities and differences across patenting systems. Protecting Inventions in the U.S. and Europe: Inventors Need to Be Cognizant of Patent Laws on Both Sides of the Atlantic
• Gail Dutton, Genetic Engineering & Biotechnology News, discusses the FDA office at the U.S. embassy in Beijing which was opened in an effort to implement a cost-effective, prevention-based approach to risk management. FDA Seeks to Establish Branch Office in China: Will It Truly Overcome Safety Concerns or Is It Just Window Dressing?
• Janis K. Fraser, Ph.D. Genetic Engineering & Biotechnology News, suggests that existing gene patents and applications being considered face an uphill battle. U.S. Gene Patents in Legal Limbo -- for Now. USPTO's Rejection of Kubin Patent Due to Obviousness Raises Questions
• Jeffrey Gibbs, Genetic Engineering & Biotechnology News, states that it is critical for IVD companies to carefully draft their intended use early in the regulatory process. Adroit Crafting of 'Intended Use' Critical: Regulatory Fate of a New IVD May Well Depend on a Few Dozen Words.
• Beverly Lubit, Ph.D., Genetic Engineering & Biotechnology News, thinks it would be far simpler for Congress to give the USPTO the funds it needs to hire qualified examiners to do its job. New Act Endangers Long-Term Patent Validity Economic Ramifications of Postgrant Review as Proposed by the Reform Act of 2007
• Stephen B. Maebius, Judith A. Waltz, David Rosen and Sean Tu of Foley & Lardner, LLP, report on the growing universe of potentially patentable risk mitigation strategies. Patenting Risk Evaluation & Mitigation Strategies for Pharmaceuticals: A New Life Cycle Mgmt Target for Patents
• Ben McLaughlin and Antonia Abelson, Baker & McKenzie, share their thoughts on the growing trend of Advisory Boards and the promises and pitfalls to consider. Advisory Boards - Beware the Fiduciary Obligation
• Glenn Perdue, Kraft Analytics, LLC,lays out the benefits to businesses and consumers from a clearer, fairer patent system. The Economics of Judicial Patent Reform in the United States
• Ronald A. Rader, Genetic Engineering & Biotechnology News, says 2007 was an unproductive year for biopharmaceutical approvals and more study is needed to determine why. Paucity of Biopharma Approvals Raises Alarm: Lower Numbers, Novelty, and Economic Impact Indicate Problems
• Jonathan E. Rackoff, J.D., Genetic Engineering & Biotechnology News, says evidence strongly implies that protecting human subjects may be outside the perimeter of FDA’s traditional, and likely future, competencies. Improving Protection of Trial Participants Proposed Ethics Organization Would Beef-up Oversight of a Critical Area Neglected by FDA
• Peter S. Spivack, Genetic Engineering & Biotechnology News, says DOJ has firmly taken control of off-label use allegations against pharmaceutical, biotechnology, and medical device manufacturers. Off-Label Promotion Under Scrutiny by DOJ: The Department of Justice Is Aggressively Pursuing Healthcare Fraud Allegations
• Anthony Tridico, Jim Kastenmayer and Ali Kargbo, Genetic Engineering & Biotechnology News, warn that the patent application backlog is certain to grow in the future. USPTO Backlog Impacts Biopharma Industry: Unless Situation Is Resolved, Investment in New Candidates May Be Delayed or Withheld Accordingly
• Tamsen Valoir, PhD, JD, LLM and Michael Dai, Ms, JD, IP & Technology Law Journal, encourage prioritizing your diligence dollars wisely to ensure a deals’ long term success. M&A: Effective Global IP Due Diligence
• Kathryn H. Wade, Ph.D. and John K. McDonald, Ph.D., Kilpatrick Stockton LLP; and Hazim Ansari, Hennigan, Bennett and Dorman, offer advice on how to decide whether accelerated examination is appropriate for your patent portfolio. Strategic Considerations in Coordinating Acceleration of International Patent Prosecution
• William Warren and Donna Best, Genetic Engineering & Biotechnology News, report on the far-reaching implications in Proveris for the use of research tools to develop and test products for purposes of obtaining data for FDA approval. Is Safe Harbor Closed to Research Tools? A Receding Scope of Exemption from Patent Infringement
• William Warren and Mark Westhafer, Ph.D., Genetic Engineering & Biotechnology News, cover revised written description guidelines for use in patent applications to ensure compliance with 35 U.S.C. 112. Patent Update: Redefining Written Descriptions for Patents Biotech Inventions Must Now Face New Standards and Detailed Requirements
• George C. Yu and John Kappos, Genetic Engineering & Biotechnology News, review the first major decision regarding the standard for obviousness in over 40 years. Redefining Obviousness After KSR Decision: Eisai Provides Some Greatly Needed Predictability for Biotech and Pharma

HEAL

• Michael Feehan, Ph.D. and Rich Durante, Ph.D., Genetic Engineering & Biotechnology News, caution all stakeholders in therapeutic vaccine development not to hype potential advances to consumers. Opinion: Reining In New Therapeutic Hype Is Critical to Finding the Middle Ground Between Biotech Executive Optimism and Practitioner Pessimism
• Sarah E. Frew, Hannah E. Kettler and Peter A. Singer, Health Affairs, look at Asia's progress in growing its research-and-innovation based health biotech sectors. The Indian and Chinese Health Biotechnology Industries: Potential Champions of Global Health?
• Sarah E. Frew, Rahim Rezaie, Stephen M. Sammut, Monali Ray, Abdallah S. Daar and Peter A. Singer, Nature Biotechnology, caution that India's biotech must create large market opportunities so that products find their way to the patients who need them. India's Health Biotech Sector at a Crossroads.
• Michael Harris, BioWorld Today, makes the case that funding the genomics sector is as important as fending off negative publicity. Stem Cells: The Challenges and Opportunities
• Michael Harris and Amanda Lyle, BioWorld Today, argue that diabetes ranks as one of the world's most influential and critical dynamics affecting both the health and economy of society. Diabetes Rivals Climate Change, War, Economy in Global Relevance
• Kenneth P. Krul, Ph.D., Genetic Engineering & Biotechnology News, suggests that no matter the benefits, the use of companion diagnostic for personalized medicine applications will not have an easy route to and through the market. Pitfalls Undermine Promise of Theranostics: Challenges Create a Significant Discrepancy between Potential and Actualized Markets
• Viren Mehta, Pharm.D. and Eric Snyder, Ph.D., Genetic Engineering & Biotechnology News, predict that companies investing in large-scale, low-cost manufacturing of biosimilars now have an advantage in the future. Biosimilars Are Poised to Influence the Industry Political Interest and Physicians’ Need to Drive Down Costs Could Create a Sizable Segment
• Kathleen Kite-Powell, BioWorld Today, discusses new biocompatible materials and simulation techniques improving patient safety. For Musculoskeletal Procedures, What Challenges and Solutions Await in the Near Future?
• Kathleen Kite-Powell, BioWorld Today, describes how RNAi has the potential to cure or control a wide spectrum of diseases and conditions. RNAi as Therapy in Humans Beginning to Make a Splash; Has the Promise of Making Waves
• Stephen Simes, BioSante Pharmaceuticals, says an approved female testosterone product could satisfy a $1.5 billion to $2 billion market. Testosterone Gel for HSDD: Technology Tackles an Unmet Medical Need
• Rohini Srinivasan, HCL Technologies, discusses measures being taken in the pharmaceutical sector to curb the number of failures in new drug discovery. Biomarkers - A Paradigm Shift in Drug Discovery to Development: One Drug Many to Right Drug Right Dose Right Patient
• Mikhail Zhurkin, Oxana Pickeral, and Lucy Stribley, discuss the processing and analysis of large amounts ofbiomedical data. Rapid Learning Opportunities in Biomedical Knowledge Management: Promising Directions in Systems for Automated Correlation Inference in Large Health Care Data Sets
• Beata M.Barci, Oxana K. Pickeral, Pamela Smeder-Douglas, andLucy K. Stribely, explain challenges that introduce opportunities to test approaches to biomedical product development. Biomedical Product Portfolio Decisions: Re-Examining Ways to Evaluate Therapeutic Area Priorities

FUEL

• Michael Harris, BioWorld Today, claims even though investment has increased, much more funding will be needed to deliver on the full scope and promise of biofuels. Considerations for the Future of the Biofuels Market
• Michael Harris, BioWorld Today, says that while public opinion is favorable, we are years, even decades, away from energy independence, cheaper fuel and environmental preservation. Biofuels: Driven Past the Hype, But Not Quite Home Yet
• Amanda Lyle, BioWorld Perspectives, asks who will be the first to use synthetic biology to convert cellulose quickly and cheaply into biofuel. Synthetic Biology Emerges as Key to Biofuels Future
• Kathleen Kite-Powell, BioWorld Today, looks at the growing popularity and use of alternative fueled vehicles around the world. Ethanol-Fueled Vehicles Make Their Way Around the World

FEED

• Michael Harris, BioWorld Today, suggests that using biotech crops for fuel purposes instead of human ingestion won't put an end to the debate or help alleviate world hunger. A Practical, Non-Controversial Application for GM Food Crops
• Amanda Lyle, BioWorld Perspectives, talks to experts that say farmers can continue to increase yields of crops to meet the demands for food, feed and fuel. Cause for Concern? The Food vs. Fuel Debate in the News

WORKFORCE

• Bruce Carlson, Genetic Engineering & Biotechnology News, reports that with outsourcing on the rise, a top concern is protecting IP rights and privacy issues. Pharma Outsourcing on Upward Trajectory: Desire to Save Money, Boost Technology, and Speed Discovery Process Drives Growth
• Wendy Mack, T3 Consulting, LLC, warns against letting too much anxiety about the economy affect the bottom line. Transforming Anxiety into Energy
• Wendy Mack, T3 Consulting, LLC, says keep your pitches short and crisp so executive teams are clear about your strategy for making the organization more successful. Gaining Executive Support
• Wendy Mack, T3 Consulting, LLC, describes how corporate executives and managers can reduce employee anxiety and increase workforce productivity despite the troubling economy. Communicating with Employees in Turbulent Times
• Bryan Pearce, Genetic Engineering & Biotechnology News, sees continuing growth in the job market and suggests companies plan employee attraction and retention policies carefully. Life Science Compensation Trends Upward: Knowing What Other Firms Are Doing Can Help when Establishing Remuneration for Personnel
• Christine Pescatore, IBM Southeast Employees; Federal Credit Union, parent company of PGA Credit Union, outlines how offering credit union membership can increase acquisition and retention of employees. What Can a Credit Union Do for Your BioTech Company?
• John Sterling, Genetic Engineering & Biotechnology News, highlights a series of recommendations for future bioscience education. Strengthening the Biotechnician Workforce: National Science Foundation Conference Focuses on Training and Education Issues
• David Zinger and 52 members of the Employee Engagement Network, briefly answer the question: What advice would you give an organization to improve employee retention? Employee Engagement Advice in One Sentence

MANAGING YOUR CAREER

• Jeff Carleton and Megan Driscoll, PharmaLogics Recruiting, suggest finding the right recruiter can open up a world of new and exciting possibilities. Strategies for Selecting & Working Effectively with a Recruiter
• Megan Driscoll, PharmaLogics Recruiting, explains the interviewing process in four parts and offers valuable tips to land your dream job. Interviewing Tips for the Bio-Pharma Industry
• Megan Driscoll and Scott Szczesny, PharmaLogics Recruiting, say a successful career depends on staying proactive, anticipating potential problems and developing a plan of action ahead of time. Getting Ahead: Advancing Your Career Through Strategic Job Searching

SOCIAL MEDIA TOOLS

• John Jantsch, Duct Tape Marketing, offers a practical guide for those thinking about Twittering at the office. Using Twitter for Business

MARKETING & ADVERTISING

• C. Anthony Jones, MD and Kristin Tedesco, Next Lifesciences, LLC, list common marketing mistakes to avoid to protect your investment and grow your business. Seven Deadly Sins of Marketing
• Wendy Macias, Ph.D., Genetic Engineering & Biotechnology News, calls on pharma and ad agencies take the time to convey information that resonates with the consumer and what isimportant to them. Marketing Analysis: What Is the Future of DTC Drug Advertising? Content Analysis of Direct-to-Consumer Television Ads Yields Interesting Results

GREEN TRENDS

• Vicki Glaser, Genetic Engineering & Biotechnology News, says companies and institutions need not look far beyond their own walls to reap economic gains from switching to greener chemistries. Pharmaceutical Manufacturing Goes Green: New Trends in Chemistry Will Reduce Environmental Impact of Bioprocessing